Who is sponsoring NCT04762511?

NCT04762511 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT04762511?

Interventions in NCT04762511: Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline).

What condition does NCT04762511 study?

NCT04762511 studies Herpes Simplex.

Is NCT04762511 still recruiting?

NCT04762511 is currently terminated. Last updated 28 June 2021.

Last reviewed 2021-06-28 · How we verify

NCT04762511

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Terminated Phase 1 Last updated 28 June 2021

What this trial tests

Phase 1 trial testing Lower dose formulation of HSV vaccine (GSK4108771A) in Herpes Simplex in 17 participants. Terminated before completion.

Timeline

2 March 2021

Primary endpoint
26 May 2021

26 May 2021

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	17
Start date	2 March 2021
Primary completion	26 May 2021
Estimated completion	26 May 2021
Sites	2 locations across United States

Drugs / interventions tested

Lower dose formulation of HSV vaccine (GSK4108771A) — full drug profile →
Low dose formulation of HSV vaccine (GSK4108771A) — full drug profile →
Medium dose formulation of HSV vaccine (GSK4108771A) — full drug profile →
High dose formulation of HSV vaccine (GSK4108771A) — full drug profile →
Placebo (saline)

Conditions studied

Herpes Simplex — all drugs for Herpes Simplex →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 40, any sex, with Herpes Simplex. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered intramuscularly (IM) on a 0, 2-month schedule to healthy participants aged 18-40 years.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Next generation self-replicating RNA vectors for vaccines and immunotherapies.
Aliahmad P, Miyake-Stoner SJ, Geall AJ, Wang NS. · · 2023 · cited 34× · PMID 35194198 · DOI 10.1038/s41417-022-00435-8
A review of HSV pathogenesis, vaccine development, and advanced applications.
Bai L, Xu J, Zeng L, Zhang L, et al · · 2024 · cited 30× · PMID 39207577 · DOI 10.1186/s43556-024-00199-7

Verify or expand the search:

Other recruiting trials for Herpes Simplex

Currently open trials in the same condition.

NCT04065971 — Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections. · Phase 4 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04762511 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 28 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04762511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing